Latest Breaking News On - Polish national center - Page 1 : comparemela.com

WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “ Company” or “ WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it has been conditionally awarded a grant of $6,730,036 (20,394,049.68 PLN) from the Polish National Center for Research and Development (“ NCRD”), for the development of Annamycin, the Company’s drug candidate used in the treatment of Acute Myeloid Leukemia (“ AML”). Annamycin is a “next generation” anthracycline, that has been shown to be less cardiotoxic compared to other anthracycline, such as doxorubicin, and to avoid multidrug resistance, so the use of Annamycin may not face the same dose limitations imposed on doxorubicin. The project entitled: “A novel approach to the therapy of acute myeloid leukemia (AML)” will be co-financed by the European Union, from the European Regional Development Fund, under the Smart Growth Operational Program 2014-2020. The funds will be used on the continued development of An

New yorkUnited statesUnited kingdomBritish columbiaMariusz olejniczakThomas renaudEuropean regional development fundNational centerMoleculin biotech incInvestment decisionsWake forest university health sciencesSmart growth operational programNeither the canadian securities exchangeEuropean unionInvestment industry regulatory organization of canadaPharmaceuticals inc